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Elevated serum transaminases in patients
with Mycoplasma pneumoniae pneumonia
The recent report in CMI by Daxboeck et al. [1]
described a study in which serologically diag-
nosed patients with Mycoplasma pneumoniae
community-acquired pneumonia (CAP) were
compared with 38 patients with Streptococcus
pneumoniae CAP. Increased M. pneumoniae IgM
titres suggest current or recent respiratory tract
infection, but the authors based their diagnosis of
Mycoplasma CAP on ‘highly elevated complement
ﬁxation antibody titres’ which, if unspeciﬁed,
usually indicate IgG immunoglobulins [2]. Eleva-
ted IgG titres indicate past exposure ⁄ infection,
and are not diagnostic of acute infection, although
a > 4-fold increase in IgG titres also suggests
recent infection. The authors reported that serum
alanine transaminase (ALT) levels were increased
in 36% of patients with elevated complement
ﬁxation IgG Mycoplasma titres [1].
Serological diagnosis is fraught with interpre-
tational difﬁculties without clinical correlations.
The report does not provide any description
of extra-pulmonary ﬁndings characteristic of
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Fig. 1. Serum procalcitonin (PCT), log PCT, C-reactive protein, white blood cell (WBC) counts and non-segmented
neutrophils (median, interquartile range, outliers, and extreme cases of individual variables) in patients with typical,
atypical and unknown aetiology of pneumonia.
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M. pneumoniae CAP, e.g., bullous myringitis ⁄ otitis,
non-exudative pharyngitis, erythema multiforme,
or watery diarrhoea. [3,4]. The data are difﬁcult to
interpret because there is insufﬁcient clinical ⁄
laboratory information regarding other possible
causes of elevated ALT levels in the patients
studied. Increased serum ALT levels are a com-
mon ﬁnding in CAP caused by atypical Legionella,
psittacosis, Q fever and adenoviruses. It is likely
that some ⁄many of the patients with elevated
serum ALT levels had CAP caused by Legionella,
psittacosis, Q fever or adenovirus. Without speci-
ﬁc testing for these aetiologies of CAP, it is difﬁcult
to draw ﬁrm conclusions regarding increased ALT
levels from the data [5–12].
Increased ALT levels may also be caused by a
variety of medications that affect the liver, as well
as by hepatically eliminated antibiotics. Ten of the
12 patients received macrolides, which may have
been responsible for some ⁄many elevated ALT
levels [13]. Besidesmacrolides, there are alsomany
medications that are used commonly and cause
drug fevers in hospitalised patients, and that cause
mild increases in serum ALT levels [14,15].
In addition to the laboratory information pro-
vided, epidemiological data would be helpful in
suggesting or eliminating Q fever or psittacosis.
Clinical descriptions would have been helpful;
for example, how many patients had the pro-
longed non-productive dry cough typical of M.
pneumoniae CAP? How many had non-exudative
pharyngitis, ear ﬁndings (bullous myringi-
tis ⁄ otitis) or erythema multiforme often associ-
ated with Mycoplasma? How many patients in the
study had relative bradycardia suggestive of
Legionella, Q fever, or psittacosis (but not Myco-
plasma)? These clinical features would help to
clarify whether the patients had CAP caused by
M. pneumoniae or were infected with another
atypical pathogen associated with increased
serum ALT levels. Similarly, non-serological
laboratory tests would be helpful. How many of
these patients had highly elevated cold aggluti-
nin titres (> 1:64) suggesting acute M. pneumoniae
respiratory infection rather than past exposure?
How many had microscopic haematuria or mild
renal insufﬁciency suggestive of Legionella, but
not Mycoplasma, CAP? How many had the
watery diarrhoea that is commonly present in
cases of M. pneumoniae or Legionella CAP [5,6]?
Until there is a deﬁnitive study with histolog-
ically proven liver involvement in M. pneumoniae
CAP, clinicians should view increased serum ALT
levels in a patient with CAP as being associated
with Legionella, psittacosis, Q fever or adenovirus
until proven otherwise. Elevated M. pneumoniae
IgM titres, highly elevated cold agglutinin titres
(‡ 1:64), or the recovery of the organism from
respiratory secretions in a patient with typical
clinical manifestations of Mycoplasma CAP, con-
ﬁrm the diagnosis.
Although anything is possible in medicine,
hepatic involvement manifested by increased
ALT levels in M. pneumoniae CAP should still be
regarded as rare [5,16]. In patients with CAP,
increasedALT levels, evenwith increasedM. pneu-
moniae IgG titres, should suggest an alternative
diagnosis until there is proof to the contrary.
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REPLY FROM DR DAXBOECK
We thank Dr Cunha for his interesting comments
concerning our study [1] and would like to
address the speciﬁc points raised.
The ﬁrst comment of Dr Cunha refers to the
diagnosis of Mycoplasma pneumoniae infection by
highly elevated antibody titres. We stated specif-
ically in our report that patients with titres ‡ 1:256
by complement ﬁxation test or ‡ 1:1280 by micro-
particle agglutination assay were included in the
study. These titres are diagnostic for acute M.
pneumoniae infection [2]. The comment that the
complement ﬁxation test (and the same objection
may be made concerning the microparticle agglu-
tination assay) ‘usually indicates IgG immuno-
globulins’ should be subject to further debate. It
is, of course, correct that these tests are not
designed to distinguish between IgG and IgM
antibodies. Speciﬁc IgGs are produced in larger
quantities than IgM during infection, and persist
for a longer time after infection. Therefore, low
positive titres may be caused by speciﬁc IgG
antibodies. However, importantly, both tests are
very sensitive for speciﬁc IgM, and speciﬁc IgM
formation results in a signiﬁcant rise in both
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complement ﬁxation and microparticle agglutin-
ation titres [17,18]. The obvious shortcoming of
these tests is that low positive titres are difﬁcult to
interpret, because they may be caused by either a
past infection or the beginning of a new infection.
This poses signiﬁcant problems in individual
patients. In contrast, high titres are mostly caused
by the presence of speciﬁc IgM, and are diagnostic
of acute M. pneumoniae infection. The problem of
low positive titres being difﬁcult to interpret is
easily overcome in a retrospective format by
choosing a high cut-off value, as was done in
our own study. In this context, it should be
mentioned that the real shortcoming of the study
was that the results were derived from patients
with very high antibody titres, and thus may not
necessarily apply to patients with lower titres, i.e.,
with a less pronounced immune response. Cold
agglutinins are the ﬁrst antibodies to appear in
the course ofM. pneumoniae infection, and the ﬁrst
antibodies to decrease after acute infection. In
some situations, particularly if more advanced
tools for Mycoplasma diagnosis are unavailable,
cold agglutinins may be helpful. However, if
assays for detection of speciﬁc antibodies are
available and patients are selected for retrospec-
tive analysis, testing cold agglutinins would
mean going one step back with regard to specif-
icity [19].
Dr Cunha states that serological diagnosis is
problematic without clinical correlations, which is
unquestionably true. However, in our study, all
patients had community-acquired pneumonia
(CAP) diagnosed by the responsible physicians,
followed by, as part of the study, re-review of the
chest X-ray results. CAP is a consistent clinical
correlation with regard to Mycoplasma infection.
We believe that additional clinical data would not
have improved the study signiﬁcantly, as it has
been shown that Mycoplasma pneumonia cannot
be distinguished from CAP caused by other
pathogens on the basis of clinical ﬁndings in
individual patients [20].
All non-respiratory manifestations of M. pneu-
moniae infection mentioned by Dr Cunha, inclu-
ding watery diarrhoea, ear symptoms and
erythema multiforme, occur in a minority of
patients, and are not speciﬁc for Mycoplasma
infection [21]. Therefore, the presence of these
manifestations shouldnot be used to either conﬁrm
or rule out aMycoplasma aetiology for pneumonia.
They may, however, be used as additional inclu-
sion criteria todeﬁnea studypopulation, but sucha
study population could hardly be claimed to be
representative of patients with M. pneumoniae
pneumonia in general [7].
Another comment by Dr Cunha referred to
other possible explanations for the elevated alan-
ine aminotransferase (ALT) levels in our patients.
Particularly in a purely retrospective study, a
failure to consider confounding factors may wea-
ken the interpretation of the results. However,
speciﬁcally for this reason, a control group was
included, consisting of patients with CAP caused
by Streptococcus pneumoniae. To the best of our
knowledge, none of the other potential explana-
tions for elevated ALT levels mentioned by
Dr Cunha (i.e., medication or other infectious
diseases) had a greater association with the
Mycoplasma group than with the S. pneumoniae
group. No infection with Legionella, Coxiella bur-
netii, Chlamydia psittaci or adenovirus was docu-
mented for the patients studied, although the
possibility of co-infections being overlooked in
the course of routine diagnosis cannot be ruled
out entirely. However, the probability of such
co-infections would be identical in theM. pneumo-
niae group and the control group. As highlighted
by Dr Cunha, macrolides may cause elevated ALT
levels. However, as stated in our report, the ALT
levels decreased during macrolide therapy for
most patients.
WhilewelcomingDrCunha’s comments,we still
conclude from the data obtained that ignoring the
possibility of elevated ALT levels in patients with
Mycoplasma pneumonia may lead to an incorrect
differential diagnosis for patients with CAP.
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